Author

M. Madai

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Approach:deep learning· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Organism:mouse· 1 Approach:statistical model· 1

Frequent Co-Authors

F. Jakab· 3 shared G. Kemenesi· 3 shared B. Zana· 2 shared F. Foldes· 2 shared H. Papp· 2 shared S. Zeghbib· 2 shared Z. Lanszki· 2 shared A. J. Hume· 1 shared

Activity by Year

2020-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 39 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

F. Jakab

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Reservoir host studies of Lloviu virus: first isolation, sequencing and serology in Schreiber's bats in Europe

G. Kemenesi, G. E. Toth, M. Mayora-Neto, S. Scott, N. Temperton, E. Wright, E. Muhlberger, A. J. Hume, B. Zana, S. A. Boldogh, T. Gorfol, P. Estok, Z. Lanszki, B. A. Somogyi, A. Nagy, , F. Jakab

This study isolates and characterizes Lloviu virus from Schreiber's bats in Europe, showing its ability to infect human and monkey cells and suggesting potential spillover risks.

bioRxiv · Aug 10, 2021Microbiology

Small interfering RNAs are highly effective inhibitors regarding Crimean-Congo hemorrhagic fever virus replication in vitro

F. Foldes, M. Madai, H. Papp, G. Kemenesi, B. Zana, L. Geiger, K. Gombos, B. Somogyi, I. Bock-Marquette, F. Jakab

This study identifies four siRNAs that effectively inhibit CCHFV replication in vitro by targeting all three viral genome segments.

Molecules · Dec 7, 2020Peer-reviewedMicrobiology

The Anti-histamine Azelastine, Identified by Computational Drug Repurposing, Inhibits SARS-CoV-2 Infection in Reconstituted Human Nasal Tissue In Vitro

R. Konrat, H. Papp, V. Szijarto, T. Gesell, G. Nagy, M. Madai, S. Zeghbib, A. Kuczmog, Z. Lanszki, Z. Helyes, G. Kemenesi, F. Jakab, E. Nagy

This paper identifies azelastine, an anti-histamine drug, as a potential inhibitor of SARS-CoV-2 infection through computational repurposing and in vitro testing in human nasal tissue.

bioRxiv · Sep 15, 2020 · PreprintMicrobiology